HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Premenstrual dysphoric disorder — Clinical Guidelines

Overview

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome characterized by significant emotional and physical symptoms that occur cyclically during the luteal phase of the menstrual cycle and remit with menstruation 1 10.

Diagnosis

Key Criteria: Symptoms must be present in the final week of the luteal phase and remit by the follicular phase, confirmed prospectively over at least two menstrual cycles 1 10.

Recommended Tests: Daily symptom tracking diaries are essential for diagnosis 1 5.

Grading: ICD-10 criteria should be used for formal diagnosis 10.

Management

First-Line Treatments:

- Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine (e.g., 20-50 mg daily) is commonly recommended 10. - Combined Oral Contraceptives: Drospirenone/ethinylestradiol (24/4 regimen) may offer relief, particularly in those with associated acne or mood disturbances 6 7.

Adjunctive Treatments:

- Vitamin D Supplementation: Beneficial in adolescents with severe hypovitaminosis D 4. - Nutritional Supplements: Calcium and vitamin C status may influence symptom severity; specific dosing not universally standardized 11 2.

Special Populations

Pregnancy: Limited evidence; focus on symptom management through lifestyle and non-pharmacological interventions 15.

Pediatrics: Vitamin D supplementation may help in severe cases with hypovitaminosis D 4.

Comorbidities: PMDD often coexists with major depression and anxiety disorders; integrated psychiatric care recommended 9.

Key Recommendations

Use daily symptom diaries for at least two menstrual cycles to confirm PMDD diagnosis (Evidence: Strong 1 5).

Initiate treatment with SSRIs, such as fluoxetine, for moderate to severe PMDD (Evidence: Strong 10).

Consider drospirenone/ethinylestradiol for patients with PMDD who also have acne or mood-related symptoms (Evidence: Moderate 6 7).

Evaluate and address vitamin D deficiency in adolescents with PMDD (Evidence: Moderate 4).

Integrate psychiatric evaluation and treatment for comorbid depression and anxiety in PMDD patients (Evidence: Moderate 9).

Physicians should adhere to prospective symptom monitoring guidelines for accurate diagnosis, despite variability in practice (Evidence: Expert opinion 5).

References

1 Reilly TJ, Patel S, Unachukwu IC, Knox CL, Wilson CA, Craig MC et al.. The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis. Journal of affective disorders 2024. link 2 Zeitoun T, El-Sohemy A. Associations Between Dietary Vitamin C, Serum Ascorbic Acid, and . Journal of the American Nutrition Association 2023. link 3 Michopoulos V. Stable hormones for stable moods. Science translational medicine 2017. link 4 Tartagni M, Cicinelli MV, Tartagni MV, Alrasheed H, Matteo M, Baldini D et al.. Vitamin D Supplementation for Premenstrual Syndrome-Related Mood Disorders in Adolescents with Severe Hypovitaminosis D. Journal of pediatric and adolescent gynecology 2016. link 5 Craner JR, Sigmon ST, McGillicuddy ML. Does a disconnect occur between research and practice for premenstrual dysphoric disorder (PMDD) diagnostic procedures?. Women & health 2014. link 6 Machado RB, Pompei Lde M, Giribela AG, Giribela CG. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Women's health (London, England) 2011. link 7 Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 2007. link 8 Dickerson V. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. The Journal of reproductive medicine 2002. link 9 Breaux C, Hartlage S, Gehlert S. Relationships of premenstrual dysphoric disorder to major depression and anxiety disorders: a re-examination. Journal of psychosomatic obstetrics and gynaecology 2000. link 10 Ling FW. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. The Journal of clinical psychiatry 2000. link 11 Thys-Jacobs S. Micronutrients and the premenstrual syndrome: the case for calcium. Journal of the American College of Nutrition 2000. link 12 Mira M, Stewart PM, Abraham SF. Vitamin and trace element status in premenstrual syndrome. The American journal of clinical nutrition 1988. link 13 Abraham GE, Rumley RE. Role of nutrition in managing the premenstrual tension syndromes. The Journal of reproductive medicine 1987. link 14 Stewart A. Clinical and biochemical effects of nutritional supplementation on the premenstrual syndrome. The Journal of reproductive medicine 1987. link 15 True BL, Goodner SM, Burns EA. Review of the etiology and treatment of premenstrual syndrome. Drug intelligence & clinical pharmacy 1985. link 16 Damas-Mora J, Davies L, Taylor W, Jenner FA. Menstrual respiratory changes and symptoms. The British journal of psychiatry : the journal of mental science 1980. link

Premenstrual dysphoric disorder